Clinical Burden of Aripiprazole Once-Monthly in Patients With Schizophrenia Receiving Antipsychotic Polypharmacy
10.22857/kjbp.2024.31.2.003
- Author:
Jiwan MOON
1
;
Hyeryun YANG
;
Sra JUNG
;
Soo Bong JUNG
;
Jhin-Goo CHANG
;
Won-Hyoung KIM
;
Sang Min LEE
;
Jangrae KIM
;
Minji BANG
;
Min-Kyoung KIM
;
Eun Soo KIM
;
Dong-Won SHIN
;
Kang Seob OH
;
Sang Won JEON
;
Junhyung KIM
;
Young Chul SHIN
;
Sung Joon CHO
Author Information
1. Department of Psychiatry, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea
- Publication Type:ORIGINAL ARTICLE
- From:Journal of the Korean Society of Biological Psychiatry
2024;31(2):34-39
- CountryRepublic of Korea
- Language:English
-
Abstract:
Objectives:This study aimed to assess the clinical burden, a critical determinant of medication adherence in patients with schizophrenia, after the administration of Aripiprazole once-monthly (AOM).
Methods:This study was a retrospective, non-interventional, multicenter, naturalistic observational study conducted through the analysis of participants’ electronic medical records. Study participants were recruited from eight sites. Data were collected at baseline, defined as the time of AOM administration, and at 1, 3, 6, 9, and 12 months thereafter. The primary outcome measure was the change in the Clinical Global Impression-Clinical Benefit (CGI-CB) score over 12 months, and the secondary outcome measure was the change in the Clinical Global Impression-Improvement (CGI-I) score.
Results:The data of 139 participants were analyzed, revealing a statistically significant decrease of 26.8% in CGI-CB scores and 13.4% in CGI-I scores over 12 months. Upon comparison between adjacent visit intervals, significant reductions were observed for both measures between month 3 and month 6.
Conclusions:This study is the first multicenter investigation to simultaneously evaluate the clinical efficacy and tolerability of transitioning to AOM in the context of polypharmacy. The study suggested that AOM may contribute to reducing the clinical burden, thereby improving the quality of life for patients with schizophrenia.
